Ocuphire Pharma has enrolled the first patients in a phase 2 proof of concept trial evaluating a combination of Nyxol and pilocarpine for the treatment of presbyopia, according to a press release.
VEGA-1 is a double-masked, randomized, placebo-controlled multicenter trial evaluating 0.75% Nyxol (phentolamine mesylate) in combination with 0.4% pilocarpine. The trial is aiming to include 152 patients with a clinical diagnosis of presbyopia.
“We believe that the combination of Nyxol and low-dose pilocarpine has an ideal product profile to become a promising treatment for presbyopia,”
Uncategorized